NCT00351975 - Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

Accelerated Phase of DiseaseAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLLAdult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARAAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeBlastic PhaseChronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Myelomonocytic Leukemiade Novo Myelodysplastic SyndromeMyelodysplastic/Myeloproliferative Neoplasm, UnclassifiablePhiladelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous LeukemiaPreviously Treated Myelodysplastic SyndromePrimary MyelofibrosisRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaRecurrent DiseaseSecondary Acute Myeloid LeukemiaSecondary Myelodysplastic Syndrome

Interventions

DRUG

Belinostat

Given IV

DRUG

Azacitidine

Given SC

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (4)

8022

Princess Margaret Hospital, Cashmere

53792

University of Wisconsin Hospital and Clinics, Madison

60637

University of Chicago Comprehensive Cancer Center, Chicago

M5G 2M9

University Health Network-Princess Margaret Hospital, Toronto

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH